

From: [Trials](#)
To: [Border, Scott](#); [Trials](#)
Cc: megan.raymond@groombridgewu.com; Novo-Semaglutide-IPR@groombridgewu.com; [Wong, Jovial](#)
Subject: RE: Petition IPR2024-00009 challenging 10,335,462
Date: Tuesday, February 13, 2024 11:34:15 AM

Counsel,

The parties are authorized the additional briefing as outlined in the e-mail below.

Regards,

Esther Goldschlager
Supervisory Paralegal Specialist
Patent Trial & Appeal Board
U.S. Patent & Trademark Office

From: Border, Scott <SBorder@winston.com>
Sent: Tuesday, February 13, 2024 9:51 AM
To: Trials <Trials@USPTO.GOV>
Cc: megan.raymond@groombridgewu.com; Novo-Semaglutide-IPR@groombridgewu.com; [Wong, Jovial](#) <JWong@winston.com>
Subject: Petition IPR2024-00009 challenging 10,335,462

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

Your Honors,

The Petitioner requests authorization pursuant to 37 C.F.R. §42.108(c) to file a reply to Patent Owner's Preliminary Patent Owner Response limited to 3-pages and specifically addressing Patent Owner's arguments related to § 314(a)/*Fintiv* and § 315, for which good cause exists because Petitioner could not have foreseen the arguments raised with respect to those issues. The Petitioner proposes to file its reply on or by February 21, 2024.

In addition, the Patent Owner requests authorization to file a 3-page sur-reply to Petitioner's reply and will do so within two weeks of Petitioner's filing.

The parties have met and conferred and to avoid unnecessarily burdening the Board with a dispute on these issues have agreed to this course of action subject to the Board's authorization, and we are generally available this week at the Board's convenience for a conference call if necessary.

Respectfully,

Scott Border
Counsel for Petitioner

Scott Border

Partner

Winston & Strawn LLP

1901 L Street, N.W.

Washington, D.C. 20036-3506

D: +1 202-282-5054

M: +1 703-899-4136

[Bio](#) | [VCard](#) | [Email](#) | [winston.com](#)



Any tax advice contained in this email was not intended to be used, and cannot be used, by you (or any other taxpayer) to avoid penalties under applicable tax laws and regulations.

The contents of this message may be privileged and confidential. If this message has been received in error, please delete it without reading it. Your receipt of this message is not intended to waive any applicable privilege. Please do not disseminate this message without the permission of the author. Any tax advice contained in this email was not intended to be used, and cannot be used, by you (or any other taxpayer) to avoid penalties under applicable tax laws and regulations.